Filing Flows › Health Care › CytomX Therapeutics (CTMX)
CytomX Therapeutics (CTMX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · CytomX Therapeutics (CTMX) Q3 2026 earnings results →
Q3 2026 Revenue down 72% year over year to $1.7M
CytomX Therapeutics made $1.7M in Q3 2026 (-72% Y/Y). Operating margin n/m, net loss $20.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.7M in Q3 2026, down 72% year over year and up 19% from the previous quarter.
Operating costs exceeded revenue by $23.5M, an operating margin of -1392.3%. Total costs grew 16% against a revenue fall of 72%. The fastest-growing cost line was General & admin (+36%). The quarter ended with a net loss of $20.0M, narrower than the previous quarter's $20.7M loss.
Operating cash flow was $16.6M. Non-cash charges added back $2.8M of share-based compensation. Working capital and other items added $33.8M. Capital expenditures of $589K left free cash flow of $16.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $1.7M | -72% | n/m | −$20.0M | $16.6M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $1.4M | -92% | n/m | −$20.7M | −$18.1M |
| Q1 2026 | 10-Q | May 7, 2026 | $10.3M | -80% | -191.8% | −$18.2M | −$25.5M |
| Q4 2025 | 10-K | Mar 16, 2026 | $663K | -98% | n/m | −$26.5M | −$23.2M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $6.0M | -82% | -264.4% | −$14.2M | −$15.5M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $18.7M | -26% | -6.9% | −$154K | −$15.8M |
| Q1 2025 | 10-Q | May 12, 2025 | $50.9M | +23% | 44.4% | $23.5M | −$21.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About CytomX Therapeutics
We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology. CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform. This versatile, multi-modality platform is built on a strong foundation of tumor biology expertise, including deep knowledge of tumor-associated enzymes known as proteases. Our masking strategy is designed to reduce binding of biologic therapeutics to their targets until the mask is removed by proteases in the tumor microenvironment, providing more selective targeting of the tumor and optimizing the predicted therapeutic index of our clinical candidates.
In its own words, from its 10-K, filed Mar 16, 2026.
CytomX Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -72% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CTMX CytomX Therapeutics | Q3 2026 | $1.7M | -72% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: CytomX Therapeutics 10-Q on SEC EDGAR · CIK 1501989 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns CTMX and who is buying
More on CTMX
- How CytomX Therapeutics makes money: revenue by segment
- CytomX Therapeutics next earnings date and what analysts expect
- CytomX Therapeutics stock forecast, price target and fair value
- Who owns CytomX Therapeutics stock: holders, funds and Congress trades
- CytomX Therapeutics guidance and outlook
- CytomX Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results